Brief: Y-mAbs Reports Fourth Quarter 2024 Financial Results

Y-mAbs Therapeutics

04/03/2025 12:06

March 4 (Reuters) - Y-mAbs Therapeutics YMAB.O:

Y-MABS THERAPEUTICS Q4 PRODUCT REVENUE USD 26.5 MILLION

2025 ANTICIPATED TOTAL REVENUES EXPECTED TO BE BETWEEN $75 MILLION AND $90 MILLION

:  CASH AND CASH EQUIVALENTS ANTICIPATED TO BE SUFFICIENT TO FUND OPERATIONS AS CURRENTLY PLANNED INTO 2027

OUTLOOK Q1 REVENUES EXPECTED TO BE BETWEEN $18 MILLION AND $21 MILLION

Q1 REVENUE VIEW $24.4 MILLION -- LSEG IBES DATA

FY2025 REVENUE VIEW $104.5 MILLION -- LSEG IBES DATA

: QTRLY LOSS PER SHARE $0.15

Q4 EARNINGS PER SHARE VIEW $-0.12, REVENUE VIEW $27.3 MILLION -- LSEG IBES DATA

Source text: ID:nGNX9cTcbF

Further company coverage: YMAB.O

 ((Reuters.Briefs@thomsonreuters.com;))